Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II experimental, open-label, dose escalation, active treatment study
designed to determine the safety, tolerability, and recommended dose of the combination.
During the Phase 2 portion of the study, we will assess progression-free survival (PFS),
overall survival (OS),overall response rate (ORR), correlative endpoints, DNA methylation
measured by microarray, and expression level of the genes as measured by microarray